Immunotherapeutic approaches for the treatment of malignant melanoma

Current Opinion in Investigational Drugs

Volumn 2, Issue 11, 2001, Pages 1553-1563

  Curiel Lewandrowski, C ^a   Atkins, M B ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

IFN ; IL 2; Immunotherapy; Malignant melanoma; Monoclonal antibody; Vaccines

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; BYSTRYN VACCINE; CANCER VACCINE; CISPLATIN; DACARBAZINE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE ANTIBODY 3F8; GANGLIOSIDE ANTIBODY R24; HYBRID PROTEIN; IMMUNOGLOBULIN G ANTIBODY; MELACINE; MELANOMA VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HU-MAB L72; PHOSPHORYL LIPID A; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT CYTOKINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL OBSERVATION; CLINICAL TRIAL; DENDRITIC CELL; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; GENE THERAPY; HUMAN; IMMUNE RESPONSE; MELANOMA; REVIEW;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; MELANOMA;

EID: 0035182099     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. Malignant melanoma: Prevention, early detection, and treatment in the 21st century
2. Recent trends in cutaneous melanoma incidence among whites in the United States
3. Duration of survival for disseminated malignant melanoma: Results of a meta-analysis
4. The interferons
5. Interferons in dermatology: Present day standard
6. Biological activity of recombinant human interleukin-2 produced in Escherichia coli
7. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
8. High- and low-dose interferon α-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190
9. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected malanoma: Results of the multicenter Eastern Cooperative Oncology Group phase II trial E2696
10. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma
11. Quality-of-life-adjusted survival analysis of interferon alpha-2b adjuvant treatment of high-risk resected cutaneous melanoma: An ECOG study
12. Evaluation of efficacy of adjuvant rIFNα 2a in melanoma patients with regional node metastases
13. Interleukin-2 therapy in patients with malignant melanoma: A phase II study
14. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2
15. Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanoma
16. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
17. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update
18. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma
19. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: Results of two phase II cytokine working group trials
20. Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma
21. Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma
22. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: A pilot study
23. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma
24. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, decarbazine (CVD), interleukin-2 (IL-2) and interferon alpha-2b (IFN) in patients with metastatic melanoma
25. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma
26. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor
27. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating fractor, and TNF-alpha
28. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor
29. The role of cytotoxic chemotherapeutic agents either alone or in combination with biological response modifiers
30. Chemotherapy for metastatic melanoma
31. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus cacarbazine with tamoxifen (TMX) versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group Study (E3690)
32. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: A multicenter phase II study
33. A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring
34. Combination of chemotherapy with interleukin-2 and interferon alpha for the treatment of metastatic melanoma
35. Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatent of advanced melanoma
36. Salpêtrière Hospital experience with biochemotherapy in metastatic melanoma
37. Development and results of biochemistry in metastatic melanoma: The University of Texas M.D. Anderson Cancer Center Experience
38. Feasibility study of chemoimmunotherapy (Ch-IM) with cisplatin (CDDP) interleukin-2 (IL-2) and interferon alpha 2a (IFNα) on 14 melanoma brain metastases patients
39. A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma
40. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma
41. Chemoimmunotherapy of advanced malignant melanoma: Sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen
42. Immunogenicity of melanoma-associated gangliosides in cancer patients
43. Analysis of the antibody response to immunization with purified O-acetyl GD3 gangliosides in patients with malignant melanoma
44. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: Induction of inflammatory responses at tumor sites
45. Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside
46. Ganglioside GD2 specific monoclonal antibody 3F8: A phase I study in patients with neuroblastoma and malignant melanoma
47. Regression oef cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2
48. Pilot trial of murine monoclonal antibodies in patients with advanced melanoma
49. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy
50. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins
51. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy
52. Interleukin 2-antibody and tumor necrosis factor-antibody fusion proteins induce different antitumor immune responses in vivo
53. Vaccine therapy
54. Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma
55. Autologous, hapten-modified vaccine as a treatment for human cancers
56. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases
57. Perspective on allogeneic melanoma lysates in active specific immunotherapy
58. Clinical activity of a polyvalent melanoma antigen vaccine
59. Adjuvant therapy of intermediate-thickness node-negative melanoma with an allogeneic tumor vaccine. Southwest Oncology Group
60. Active specific immunotherapy of melanoma. Phase I trial of allogeneic melanoma lysates and a novel adjuvant
61. Significant impact of HLA class I alleles on outcome in T3N0 melanoma patients treated with Melacine
62. Vaccine therapy for malignant melanoma
63. Immunological gene therapy approaches for malignant melanoma. 1. Tumor-immunological background
64. Immunological gene therapy approaches for malignant melanoma. 2. Preclinical studies and clinical strategies
65. Interleukin-2 production by tumor cells bypasses T helper function in the generation of antitumor response
66. Immunotherapy of cancer with genetically modified tumor vaccines
67. Cytokine gene transduction in the immunotherapy of cancer
68. Gene therapy for melanoma in humans
69. Influence of gene modified (IL-4, IL-7, and B7) tumor cell vaccines on tumor antigen presentation
70. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine
71. IFN-α 1 gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice
72. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells
73. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
74. A phase I study of vaccination with autologous, GM-CSF transduced and irradiated cells in patients with advanced melanoma
75. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
76. Direct gene transfer with DNA-liposome complexes in melanoma expression, biologic activity, and lack of toxicity in humans
77. Combined experience of phase I studies with allovectin-7, a direct gene transfer immunotherapeutic, in patients with metastatic solid tumors
78. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma
79. Immune response in human melanoma after transfer of an allogeneic class I MHC gene with DNA-liposomes complexes
80. Locoregional response and increased natural killer activity after intratumoral injection of HLA-B7/beta2-microglobulin gene in patients with cancer
81. Phase II trial of HLA-B7 plasmid DNA/lipid (Allovectin-7) immunotherapy in patients with metastatic melanoma
82. Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors
83. Heat shock protein transfer peptides during antigen processing and CTL priming
84. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
85. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells
86. Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin
87. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3
88. Tumor regression has been observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
89. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma
90. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
91. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12
92. Identification of melanoma antigens recognized by T lymphocytes and their use in the immunotherapy of cancer
93. Antigen-specific tumor vaccines-development and characterization of recombinant adenoviruses encoding MART-1 and gp100 for cancer therapy
94. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
95. Immunophenotyping of melanomas for tyrosinase: Implication for vaccine development
96. Phase 2 trial of vaccination with tyrosine peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma
97. Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients
98. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma
99. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 of gp100 melanoma antigens
100. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues
101. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100
102. A Cytokine Working Group phase II trial of a modified gp 100 melanoma peptide (gp 100(209 M)) and high dose interleukin-2 administered q3 weeks in patients with stage IV melanoma: Limited antitumor activity
103. Immunogenicity of melanoma-associated gangliosides in cancer patients
104. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine
105. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma
106. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801
107. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by GM-CSF and IL-4 and downregulated by TNFα
108. Proliferating dendritic cells progenitors in human blood
109. Culture of dendritic cells from bone marrow supplemented with GM-CSF and TNF-alpha
110. Identification of proliferating dendritic cell precursors in mouse blood
111. Peptide-pulse dendritic cells induce antigen-specific, CTL-mediated prospective tumor immunity
112. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
113. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA
114. Dendritic cells as adjuvants for immune-mediated resistance to tumors
115. Gene therapy for melanoma in humans
116. Immunotherapy and experimental approaches to metastatic melanoma
117. Emerging concepts in cancer vaccine development
118. Induction of antitumor immunity using bone marrow generated dendritic cells
119. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection
120. Dendritic cells in antitumor immune responses. II: Dendritic cells grown from bone marrow precursors but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors
121. Induction of antigen-specific cytolytic T-cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells
122. Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells